Hot on the heels of their recent acquisition of Grassroots, the Food and Drug Administration has issued a warning letter to Curaleaf for allegedly “illegally selling” CBD products with “unsubstantiated claims” that the products treat cancer, Alzheimer’s disease, opioid withdrawal, […]





